Department of Medicine, Division of Hematology Oncology; Department of Pathology
Hematology | Hemic and Lymphatic Diseases | Neoplasms | Oncology
In summary, we show rapid and deep remission induced by blinatumomab in CD19(+) blast phase CML. Clinicians may consider the use of bispecific T-cell engager therapy as a bridge to transplant. Additional studies are needed before expanding the US Food and Drug Administration indication of blinatumomab to include lymphoid blast phase CML.
Chronic myeloid leukemia
Rights and Permissions
Copyright © 2021 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
DOI of Published Version
Patel SA, Bledsoe JR, Higgins AW, Hutchinson L, Gerber JM. Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase. JCO Precis Oncol. 2021 Jul 9;5:PO.21.00039. doi: 10.1200/PO.21.00039. PMID: 34409243; PMCID: PMC8367045. Link to article on publisher's site
JCO precision oncology
Patel SA, Bledsoe JR, Higgins AW, Hutchinson L, Gerber JM. (2021). Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase. Open Access Publications by UMass Chan Authors. https://doi.org/10.1200/PO.21.00039. Retrieved from https://escholarship.umassmed.edu/oapubs/4848
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.